|
|
Ezetimibe Controversy Continues: IMPROVE-IT Enlarged and Delayed, the Inside Struggle Over ENHANCE
|
| Link ID |
4513 |
| Title |
Ezetimibe Controversy Continues: IMPROVE-IT Enlarged and Delayed, the Inside Struggle Over ENHANCE |
| Url |
http://www.medscape.com/viewarticle/572404?src=rss |
| Description |
The study designed to specifically answer whether or not ezetimibe reduces hard clinical end points, known as the IMPROVE-IT study, is expected to be delayed about one year, until 2012, because investigators have added more patients, increasing enrollment from the last target of 12 500 to 18 000. Heartwire |
| Category |
Articles > Cardiology |
| Keywords |
|
| Date |
Apr 4, 2008 |
| Contact Name |
|
| Email |
|
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
|
|
Other links at Articles > Cardiology |
| 2. |
TRITON: Consistent Reduction in Stent Thrombosis Seen
|
|
|
A new analysis from the TRITON-TIMI 38 trial shows similar significant reductions in stent thrombosis with prasugrel vs clopidogrel irrespective of stent type and stent-thrombosis definition. The risk of stent thrombosis will therefore be another factor that can be considered when weighing which of these antiplatelet agents to use, TRITON investigators said. Heartwire
|
| 3. |
Blood Pressure Tracks From Childhood to Adulthood
|
|
|
A new meta-analysis of blood pressure–tracking studies shows that higher blood pressure in childhood is associated with higher blood pressure in adulthood and that early intervention is important. Medscape Medical News
|
| 4. |
Disputed Echo Results From MIST I Require Regulatory Attention, Article States
|
|
|
Dr Jonathan Tobis argues that the FDA and the MHRA in the UK should step in to clear up the "mist of confusion" created by the disparate residual-shunt data reported officially and unofficially for MIST I. While the FDA is refusing to comment, the UK agency says it has reviewed the data and found no sign of safety or efficacy problems with the STARflex device. Heartwire
|
|
|
